◼ Archived
Business
Moderna chasing ‘holy grail’ of cancer prevention
Moderna CEO Stéphane Bancel says the company's personalized mRNA cancer vaccine could work in "more cancers than melanoma" and aims for FDA approval by 2027, with shares up 750% in 2026.